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Abstract Hidradenitis suppurativa/acne inversa (HS) is a
chronic inflammatory skin disease characterized by pain-
ful, recurrent nodules and abscesses that rupture and lead
to sinus tracts and scarring. To date, an evidence-based
therapeutic approach has not been the standard of care
and this is likely due to the lack of evidence based treat-
ment guidelines. The purpose of this study was to promote
a holistic evidence-based approach which implemented
Level of Evidence and Strength of Recommendation for
the treatment of HS. Based upon the European Dermatol-
ogy Forumguidelines for the management of HS, evidence-
based approach was explored for the treatment of HS. The
diagnosis of HS should be made by a dermatologist or
other healthcare professional with expert knowledge in
HS. All patients should be offered adjuvant therapy as
needed (pain management, weight loss, tobacco cessation,
treatment of super infections, and application of appropri-
ate dressings). The treating physician should be familiar
with disease severity scores, especially Hurley staging,
physician global assessment and others. The routine use
of patient’reported outcomesincluding DLQI, itch and pain
assessment (Visual Analogue Scale) is strongly recom-
mended. The need for surgical intervention should be
assessed in all patients depending upon type and extent
of scarring, and an evidence-based surgical approach
should be implemented. Evidence-based medical treatment
of mild disease consists of topical Clindamycin 1 %
solution/gel b.i.d. for 12 weeks or Tetracycline 500 p.o.
b.i.d. for 4 months (LOE IIb, SOR B), for more widespread
disease. If patient fails to exhibit response to treatment or
for a PGA of moderate-to-severe disease, Clindamycin 300
p.o. b.i.d. with Rifampicin 600 p.o. o.d. for 10 weeks (LOE
III, SOR C) should be considered. If patient is not im-
proved, then Adalimumab 160 mg at week 0, 80 mg at
week 2; then 40 mg subcutaneously weekly should be ad-
ministered (LOE Ib, SOR A). If improvement occurs then
therapy should be maintained as long as HS lesions are
present. If the patient fails to exhibit response, then con-
sideration of second or third line therapy is required. A
growing body of evidence is being published to guide the
treatment of HS. HS therapy should be based upon the
evaluation of the inflammatory components as well as the
scarring and should be directed by evidence-based guide-
lines. Treatment should include surgery as well as medical
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treatment. Future studies should include benefit risk ratio
analysis and long term assessment of efficacy and safety, in
order to facilitate long term evidence based treatment and
rational pharmacotherapy.
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1 Introduction
Hidradenitis suppurativa/acne inversa (HS) is a chronic in-
flammatory skin disease characterized by painful, recurrent
nodules and abscesses that rupture and lead to the formation
of sinus tracts and scarring. HS has a psychologically mean-
ingful and clinically significant negative effect on the patient’s
quality of life. It is fairly common, affecting approximately
1 % of the population. Experience indicates that the patients
are only diagnosed after long delays. This may be due to the
previous orphan status of the disease. It is further speculated
that an evidence-based therapeutic approach has therefore not
been the standard of care to date. This status is likely rein-
forced by the lack of evidence based treatment guidelines.
Based upon the Guidelines for HS treatment produced by
the European Dermatology Forum [1], we are suggesting an
evidence-based approach that includes Level of Evidence
(LOE) and Strength of Recommendation (SOR) to produce
a comprehensiveand rational approach for this debilitating and
devastating chronic recurrent inflammatory disorder of the
skin.
2 Definition
HS is a chronic, inflammatory, recurrent, debilitating skin dis-
ease of the hair follicle that usually presents after puberty with
painful, deep-seated, inflamed lesions in the body folds, most
commonly the axillae, inguinal and anogenital regions, but can
affect other areas as well (modified, Dessau definition, 1st
International Conference on Hidradenitis suppurativa/Acne
inversa, March 30-April 1, 2006, Dessau, Germany) [2, 3].
3 Epidemiology
Studies which provide prevalence or incidence estimations
have been performed under different settings (hospital
versus population-based) and in different time periods. In ad-
dition, the applied diagnostic methods are varying (self-
reported, medically assessed, diagnosis of treatments codes
through automated requests in medical information systems)
and, therefore, they led to an important variability regarding
the prevalence of HS [4].
Using a health claims database, HS prevalence was esti-
mated to be 0.05 % in the USA [5]. The authors reported that
selection biasmay have influenced results, since they included
only health-insured subjects and, therefore, this prevalence
rate may not be representative for the general US population.
There may also be a classification bias as HS cases were only
identified through drug reimbursement, leading to potential
underestimations. Further analysis of the data implies impor-
tant differences in the populations identified. The mean age of
US cases was 38 years, i.e. older than the mean age of HS
patients in European studies. Hence, young patients who have
not asked for medical advice yet, may have been missed.
Two European studies have reported a prevalence of 1 %
[6, 7]. The first was a French population-based investigation
on self-declared cases in a representative sample of the French
population (10,000) [6]. Even though selection bias is unlikely
in this setting, a classification bias is likely due to self-
declaration leading to potential over-estimation of the preva-
lence rate. Jemec et al. [7] assessed a sample of 599 Danish,
clinically examined, unselected subjects and found a preva-
lence of 1 % (confidence intervals 0.4–2.2). Using a validated
questionnaire in a population sample of 16 404 persons a
possible prevalence of 2.1 % was suggested. In another study,
Jemec found a prevalence of 4 % in young adult women [8].
As HS is mainly a disease of young adults with a female
predominance, this result is not discordant with the figure of
1 % in the general population. These results are in discrepancy
with the reported equal male to female ratio of the previous
prospective study of the same authors [7].
The mean incidence of HS was assessed to be 6.0 per 100,
000 person-years, evaluated through the Rochester Epidemi-
ologic Project in an American county (Minnesota) with a pop-
ulation of about 144,000. Between 1968 and 2008 a two-fold
incidence was calculated (4 to 10 per 100,000 person-years).
This increase may be due to an increase in detection and cod-
ing of HS in the medical information system. The limitation of
the study is its retrospective design. Moreover, a selection bias
could have occurred due to recruitment through medical in-
formation system leading to a possible underestimation of
incidence, since extrapolation of the data leads to the low
prevalence of 0.08–0.20 % [9]. There also may be a classifi-
cation bias due to missed diagnosis of mild early cases.
The discrepancies between European and American studies
may be due to different methodologies but may also reflect
actual differences in prevalence/incidence of HS or different
diagnostic criteria with only the most severe cases having
been reported in the USA.
3.1 HS in children and adolescents
Data regarding HS in children and adolescents are scarce. HS
can be seen in prepubertal age. Only 2% of cases occur before
the age of 11 years [10]. In a retrospective study of 855
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patients, 7.7 % reported an onset of HS before the age of
13 years [11]. Early onset HS was associated with stronger
genetic susceptibility and more widespread disease [11]. Rec-
ommendations for treatment in this age group are based only
on case reports and extrapolation of treatments evaluated in
clinical trials in adult population [12]. Finasteride, an
antiandrogen, has been evaluated in a case series of early onset
HS [13]. Most patients had endocrine co-morbidities, like
polycystic ovary syndrome and precocious puberty. In all pa-
tients, finasteride, combined with antibiotics or other treatment
modalities, facilitated remission and improved disease severity.
Finasteride is recommended, especially in patients with refrac-
tory HS or with endocrine co-morbidities. Careful assessment
of benefits and risks with its use is crucial in this age group.
Topical clindamycin twice daily for 3 months should be
considered as first-line treatment option in mild to moderate
HS. Systemic clindamycin plus rifampicine and tetracycline
can be used, taking into careful account age restrictions, dos-
ing differences, and possible side effects. Analgesics and cor-
ticosteroids can be considered to control pain and reduce in-
flammation. Adjuvant therapy and timely treatment of super-
infections are essential. Scarring and Hurley III severity
should be treated with surgical procedures. Negative pressure
wound therapy in 30 HS patients (mean age 16 years) from a
retrospective case series provide evidence that more 87 % of
patients had successful outcomes with only 4 patients
discontinuing because of side effects [14].
4 Disease assessment
Objective disease assessment is a pre-requisite for the devel-
opment of evidence based therapy. The Hurley classification
of disease severity is the oldest and most commonly used of
the several systems that have been suggested. The Hurley
score is however a static score and not sufficiently responsive
to change, particularly relating to the inflammatory compo-
nent of HS [1]. In the past, the method of assessment was
the Sartorius Scores, but in recent clinical research this has
not been used as the primary endpoint. A newly developed
physician rated assessment is the Hidradenitis Suppurativa
Clinical Response (HiSCR) developed and validated and used
as the primary endpoint in randomized control trials studying
the use of adalimumab [15]. The HiSCR is not only a valid
and meaningful endpoint for assessing HS treatment effective-
ness in the inflammatory component of HS, but also its test-
retest reliability, convergent validity, responsiveness and pre-
dictive validity were confirmed. The HiSCR is also signifi-
cantly correlated with improvements in all physician-related
measures (Hurley Stage, modified Sartorius Scores and HS
Physicians Global Assessment), and patient reported out-
comes (visual analogue pain scale, dermatology life quality
index and work productivity and activity impairment
questionnaire). HiSCR has been used to study the effect of
adalimumab in HS and patients who continue responsiveness
had significant improvements in both physician-related and
patient-reported HS disease severity and impact [15].
5 Methods
Based upon the recently published guidelines for hidradenitis
suppurativa developed by the Guidelines Subcommittee of the
European Dermatology Forum [1], a detailed review of all
therapies was conducted. All therapeutic aspects of the treat-
ment included in the Guidelines were reviewed and a category
of evidence and strength of recommendation was developed
for the first line therapy (see Table 1) which included topical
Clindamycin, oral Clindamycin/Rifampicin, tetracycline and
subcutaneous Adalimumab. A similar approach was taken for
the second line therapies which included Zinc Gluconate, Res-
orcinol, Intralesional Corticosteroids, Infliximab, Acitretin
and Etretinate. Third line therapies evaluated include Colchi-
cine, Botulinum Toxin, Isotretinoin, Dapsone, Cyclosporine,
hormones. Surgical therapies evaluated included excision or
curettage of individual lesions, total excision of lesions sur-
rounding hair-bearing skin, secondary intention healing, pri-
mary closure, reconstructive with skin grafting and
NPWTreconstruction with flap, deroofing, carbon dioxide la-
ser therapy, Nd:YAG laser therapy andintense pulsed light
(IPL). Other aspects of treatment that were assessed include
pain control and dressings (see Table 1). Based upon the Cat-
egory of Evidence and Strength of Recommendation, an algo-
rithm incorporating all aspects of HS therapy was developed
(see Fig. 1). All therapeutic aspects with respect to HS therapy
included in the Guidelines were assessed using the Grading of
Recommendations Assessment and Evaluation (GRADE)
methodology (see Table 2) [16]. At least 2 of the authors rated
the medical and surgical treatments contained in the
Guidelines.
5.1 First-line treatment options
5.1.1 Topical clindamycin
Clindamycin lotion 1 % is the only antibiotic that has been
studied as topical agent. Its efficacy has been described in a
double-blind, placebo-controlled, randomized trial in HS pa-
tients with Hurley stage I or mild stage II [17]. It is recom-
mended as first line treatment option in patients with mild
HS-PGA or localized Hurley I/mild Hurley II stage, espe-
cially when there are no deep inflammatory lesions (ab-
scesses). The proposed dosing regimen is twice daily, for
3 months. If clinical response is not achieved after that
treatment period, other treatment options must be consid-
ered (LOE IIb; SOR B).
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5.1.2 Systemic antibiotics
Tetracycline Tetracycline 500 mg b.i.d. has been tested and
compared with topical clindamycin in a double-blind, ran-
domized, controlled trial [18]. No significant difference was
detected between the two treatment modalities. Tetracycline
500 mg b.i.d. is recommended as first line treatment option in
patients with moderate HS-PGA or more widespread Hurley
I/mild Hurley II stage, especially when there are no deep in-
flammatory lesions (abscesses), for up to 4 months. If clinical
response is not achieved after that treatment period, other
treatment modalities must be considered (LOE IIb; SOR B).
CLINDAMYCIN/RIFAMPICIN Clindamycin 300 mg
b.i.d. in combination with rifampicin 600 mg once daily or
300 mg b.i.d. has been evaluated in several case series [19].
Table 1 Category of Evidence/
Strength of Recommendation
Rating Scale
Therapy Category of
Evidence
Strength of
Recommendation
1st Line
Clindamycin (topical) 1 IIb Possible B
Clindamycin/Rifampicin (oral) 2 III C
Adalimumab (subcutaneous) 3 Ib A
Tetracycline (oral) IIb B
Surgery
Excision or Curettage of Individual Lesions III C
Total Excision of the Lesions and Surrounding Hair-Bearing Skin IIb B
Second Intention Healing IIb B
Primary Closure III C
Reconstruction with Skin Grafting & NPWT III C
Reconstruction with Flap Plasty Ia/IIa A/B
Deroofing IV D
Carbon Dioxide Laser Therapy Ib A
Nd:YAG Laser Ib A
IPL IV D
2nd Line
Zinc Gluconate III C
Resorcinol III C
Intralesional Corticosteroids IV D
Systemic Corticosteroids IV D
Infliximab Ib/IIa B
Acitretin/Etretinate III C
3rd Line
Colchicine IV D
Botulinum Toxin IV D
Isotretinoin IV D
Dapsone IV D
Cyclosporine IV D
Hormones IV D
Pain Control
NSAIDS IV D
Opiates IV D
Dressings
No studies have been published to date on the use of specific dressing or
wound care methodology in HS. Choice of dressing is based on clinical
experience.
IV D
1. Single double-blind, placebo-controlled, randomized trial. Hurley stage 1–2.
2. Evaluated in case series.
3. Multiple prospective randomized, double-blind, placebo-controlled trials (Pioneer 1 and 2).
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This treatment combination is recommended as first-line treat-
ment option in patients with moderate and severe HS-PGA or
Hurley II stage, up to 10 weeks. If clinical responses not
achieved after that treatment period, other treatment modali-
ties must be considered (LOE III; SOR C).
5.1.3 Biologic agents
Adalimumab Adalimumab sc 40 mg weekly, has been eval-
uated in a prospective, randomized, double-blind, placebo-
controlled trial [20]. It influenced positively not only the pri-
mary outcome (HiSCR), but also pain (VAS pain score),
DLQI and work productivity (TWPI score). Adalimumab is
recommended as first-line treatment option in patients with
moderate to severe HS who were unresponsive or intolerant
to oral antibiotics. It should be administered as 160 mg at
week 0, 80 mg at week 2 and 40 mg each week thereafter,
starting from week 4.If clinical response with HiSCR is not
achieved after 16 weeks of treatment, other treatment modal-
ities must be considered (LOE Ib; SORA) [21]. A preliminary
report from a subsequent RCT supports the validity of the
findings.
5.2 Second-line treatment options
5.2.1 Biologic agents
Infliximab Infliximab 5 mg/kg has been evaluated in a
randomized, placebo-controlled, cross-over trial [22]. No
significant difference in the >50 % improvement was de-
tected (primary end point), while a significantly higher
25–50 % improvement rate was detected along with pos-
itive influence in DLQI and VAS pain score. Infliximab
5 mg/kg at week 0, 2, 6 and every 2 months thereafter for
12 weeks is recommended in patients with moderate to
severe HS as second-line treatment option, only after fail-
ure of adalimumab. If clinical response is not achieved
after 12 weeks of treatment, other treatment modalities
must be considered (LOE IIa; SOR B).
Fig. 1 Algorithm
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Surgical treatment Since non-surgical methods rarely result
in lasting cure, surgical treatment is a quite common and ac-
cepted therapeutic modality for HS [1]. Surgical studies with
classical evidenced-based evaluation of efficacy are generally
sparse [23]. In agreement with the evidence paradigm of sur-
gery, only large case series and studies reporting recurrence
rates and a follow-up period of at least 1-year were therefore
included in the evaluation.
5.3 Radical surgical excision
Five studies looking at the role of radical excision (LOE IIb,
SOR B) [24–28]. The type of surgery and margins were select-
ed based on the body region and severity of the disease. A
statistically significant relationship was shown between the ef-
ficacy of a procedure and the number and severity of body
areas affected. The width of the excision and not the wound
closure technique influenced the therapeutic outcome [25, 27,
29], whereas vacuum-assisted closure may accelerate the time-
point of a delayed primary closure as shown by a retrospective
study [30]. On the other hand, secondary intention healing
revealed “good’ or “excellent” results in 27.3 % and 39.4 %,
respectively, of 97 cases studied after 12 months of follow-up
[31]. Buimer et al. [24] observed 41 % recurrences in 200
patients treated with radical surgery and closed by primary
closure or skin graft. Bieniek et al. [25] described a complete
recovery 59.7 % of 57 patients with 118 sites during a 2-year
follow-up period. Bohn and Svensson [26] described the results
of radical excision among 138 patients and follow-up from 3 to
21 years. In 38 of 116 skin-grafted patients (32.8 %) who com-
pleted a questionnaire, the disease recurred to some degree, and
14 of them required further operation. Van Rappard et al. [27]
also experienced a 34 % recurrence rate in 92 primary closed
surgically treated sites after 1–5 years follow-up. In contrast,
Rompel and Petres [28] performed radical wide excision in 106
patients with a median postoperative follow-up time of
36 months and only a 2.5 % rate of recurrence within operated
fields and wound infection in 3.7 % of patients. A retrospective
study of 106 patients treated with radical excision, whereas 100
wounds were primary closed, 29 resurfaced with split skin
grafts and 14 with local, fasciocutaneous or musculocutaneous
flaps revealed 69.9 % recurrences after primary closure and no
recurrences in the ‘graft’ and the ‘flap’ series [32]. In another
retrospective study, 31 patients undergoing drainage proce-
dures, limited regional surgery, and radical wide excisions con-
firmed the therapeutic advantage of radical excision showing
100 % recurrence after drainage, 42.8 % recurrence after lim-
ited excision, and 27 % recurrence after radical excision
(p < 0.05; mean follow-up period 72 months) [33]. Similar
results were reported by Wiltz et al. [34] in 43 patients with
perianal involvement.
5.4 Deroofing and skin-tissue-saving excision
with electrosurgical peeling (STEEP)
An open study (SORB) by van der Zee et al. [35] explored the
efficacy of deroofing in 73 lesions; 83 % showed no recur-
rence during a median follow-up period of 34 months, and
17 % showed recurrence after a median follow-up period of
4.6 months. Postoperative bleeding in 1 patient was the only
reported adverse event, and 90 % of patients responded that
they would recommend the procedure to other individuals
with HS. Blok et al. [36] evaluated retrospectively 113 pa-
tients, who underwent 482 operations (363 primary
operations and 119 re-operations) with deroofing or STEEP.
Relapses occurred after 29.2 % of primary operations in an
average follow-up period of 43 months.
5.5 Carbon dioxide LASER
Results of studies present controversial findings regarding the
use of carbon dioxide LASER surgery in HS (LOE Ib, SOR
A). Scanner assisted carbon dioxide LASER treatment under
topical anesthesia was evaluated in a retrospective clinical
study with 61 HS patients and 185 involved areas. A total
number of 154 sessions led to a 1.1 % recurrence in a
follow-up period of 1–19 years [37]. In most articles, healing
by secondary intention was used. In another retrospective
follow-up study in 34 patients with initial Hurley II stage,
who were contacted by telephone after surgery for follow-up
Table 2 Category or Evidence/
Strength of Recommendation
Rating Scale
Category of Evidence Strength of Recommendation
Ia: Meta-analysis of randomized controlled trials
Ib: Randomized controlled trial
A: Category I evidence
IIa: Controlled study without randomization
IIb: Quasi-experimental study
B: Category II evidence or extrapolated from
category I evidence
III: Non-experimental descriptive studies such as comparative,
correlation and case-control studies
C: Category III evidence or extrapolated from
category I or II evidence
IV: Expert committee reports or opinion or clinical experience
of respected authorities, or both
D: Category IVevidence or extrapolated from
category II or III evidence
Guyatt G, Oxman AD, et al. GRADE: An emerging consensus on rating quality of evidence and strength of
recommendations. BMJ April 2008; 336: 924. Last accessed February 2014.
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information, a mean healing time of 4 weeks was assessed
with a recurrence rate of 11.8 % [38]. However, new lesions
(separated from the initial surgical site by 5 cm) developed in
35.3 % of the patients, and 73.5 % of the patients had flares in
an area other than the treated site. In a recent retrospective
study involving 58 patients and the use of CO2 laser evapo-
ration of lesions in patients with HS, 95 % of the patients
reported some or great improvement, and 91 % would recom-
mend the CO2 laser surgery. 29 % reported recurrence of HS
lesions within the borders of the treated area [39].
5.6 Nd:YAG LASER
Based on the assumption that HS starts in the hair follicle, the
1064-nm neodymium-doped yttrium aluminum garnet
(Nd:YAG) laser was used in a prospective, randomized, con-
trolled study on 22 patients with stage Hurley II to III HS [40,
41]. A series of 3 monthly laser sessions were performed.
Treatment response was measured before each laser session
and 1 month after the completion of laser treatment {HS Le-
sion, Area, and Severity Index (HS-LASI) scale}. A modifi-
cation was made to include symptoms (erythema, edema,
pain, and purulent discharge; modified HS-LASI, 0–3 scale].
The percentage change in HS severity after 3 months of treat-
ment was −65.3 % over all anatomic sites, −73.4 % inguinal,
−62.0% axillary, and −53.1% inframammary. For all anatom-
ic sites combined and each individual anatomic site, the
change in HS severity from baseline to month 3 was statisti-
cally significant at the treated sites (p < .02 for modified HS-
LASI and HS-LASI), but not at the control sites (p > .05 for
modified HS-LASI and HS-LASI) (LOE Ib, SOR A). After 4
monthly sessions, a right-left, treated-untreated comparison
revealed an improvement of 72.7 % on the LASER-treated
and 22.9 % on the control averaged over all anatomic sites
(p < 0.05) [40] (LOE Ib, SOR A).
5.7 Intense pulse light
A randomized study of 18 HS patients treated at one axilla,
groin, or inframammary area with intense pulsed light twice
weekly for 4 weeks, whereas the contralateral side received no
treatment and served as a control, showed a significant im-
provement in the meanexamination score that was maintained
at 12 months (p < 0.001 logistical regression analysis). The
improvement was confirmed by independent assessment of
clinical photographs (interrater reliability, 0.79; p < 0.001)
[42] (LOE IV, SOR D).
6 BENEFIT-RISK RATIO ANALYSIS
In order to go from evidence to recommendations that facili-
tate evidence-based daily clinical practice, the balance of
desirable and undesirable outcomes of interest among alterna-
tive management strategies is becoming more and more im-
portant [43]. Benefit-risk ratio assessment with a structured
approach is a becoming an outcome of great importance for
authorities during drug regulatory decision-making as well
[44].
A structured and appropriate benefit-risk ratio analysis can
be performed only for the phase 2 trial of adalimumab, since
that is the only randomized controlled trial with a thorough
safety analysis [45]. Numbers needed to treat (NNT) for the
primary outcome of HiSCR for the phase 2 data at week 16
was 4 (95 % CI: 2.1–10.7) [46], whereas numbers needed to
harm (NNH) for any serious adverse event was 26. This fa-
vorable ratio of NNT to NHH, along with the fact that evi-
dence from phase 2 trial indicates positive effect of
adalimumab in other outcomes like DLQI, VAS pain score
and TWPI, provide the basis to recommend adalimumab as
the first-line treatment option in patients with moderate to
severe HS who were unresponsive or intolerant to oral
antibiotics.
7 Discussion
Although we present an evidence-based approach to the diag-
nosis and treatment of HS, the first and most important step is
that a dermatologist or other healthcare professional with ex-
pert knowledge in HS assess the patient and make the diag-
nosis, preferably at an early stage of the disease. Based upon
the correct diagnosis and any other significant physical find-
ings, appropriate investigations should be undertaken. HS is a
clinical diagnosis and the need for biopsy, laboratory tests,
cultures and investigations will be at the discretion of the
examining physician and based on patient history and clinical
findings. HS may be associated with comorbid diseases such
as pyoderma, arthritis, obesity, IBD, anemia, lymphedema and
metabolic syndrome [2]. Clinical evidence of any of these
associated conditions should be appropriately investigated.
Other important comorbid conditions include significant re-
duction in quality of life, depression, stigmatization and im-
pairment of sexual health [1, 47, 48]. Like the other comorbid
diseases this aspect of the disease needs to be assessed and
managed appropriately.
Treatment recommendations for the special HS patients’
group such as children and adolescents were based only on
case reports and extrapolation of clinical data in adults. Em-
phasis should be given to assessing comorbidities at baseline.
There is an obvious need for clinical data of high level to be
developed for this patient group.
As part of the holistic/broad-based approach all patients
should be offered adjuvant therapy whether it be related to
pain management, weight loss, tobacco cessation, treatment
of super infections, or implementation of appropriate
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dressings [1]. The treating physician should also be familiar
with disease severity scores, especially Hurley staging and
Physician Global Assessment. Other disease severity scores
that are important include HiSCR and Sartorius scores. Based
on the adalimumab study it is suggested that the HS clinical
response (HiSCR) [15] is currently the most appropriate clin-
ical endpoint to assess treatment and effectiveness. As men-
tioned earlier, because of the significant impact on quality of
life, patient reported outcomes are extremely important and
these should include DLQI as well as pain assessment (Visual
Analogue Scale).
With respect to surgical intervention, again this should be
assessed in each individual patient and depending upon the
type and extent of scarring, surgical procedures such as
deroofing, laser, local excision or wide excision may be
required.
Benefit-risk ratio structured assessment is needed to evalu-
ate treatments, both short and long term. An initial primary
benefit-risk ratio analysis was plausible only for adalimumab,
for the first 16 weeks of treatment, which provides evidence of
a favorable profile. Real life data from registries along with
long term efficacy and safety data from clinical trial extension
phases should be evaluated further, to assess long term benefit
risk ratio and maintenance of treatment effect, in order to
facilitate evidence based long term treatment.
8 Conclusion
A growing body of evidence is being published to guide the
treatment of HS. HS therapy should be based upon the evalu-
ation of the inflammatory components as well as the scarring
and should be directed by evidence-based therapy. Treatment
should include surgery as well as medical treatment.
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